7,640.25

+26.25

+0.34%

52,016.00

+98.00

+0.19%

28,746.75

+212.75

+0.75%

Russell 2000 Futures

2,832.90

+11.60

+0.41%

4.9290

-0.0600

-1.20%

19.42

0.00

0.00%

3,902.10

+3.20

+0.08%

78,023.25

-86.99

-0.11%

Crude Oil Dec 26

100.31

-3.81

-3.66%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - BOATS Real Time Price USD

Lakewood-Amedex Biotherapeutics, Inc. (LABT)

0.2000 -0.0373 (-15.72%)

At close: October 30 at 4:00:01 PM EDT

0.1949 -0.0051 (-2.55%)

Overnight: 2:53:28 AM EST

Loading Chart for LABT

Chart Range Bar

Interval:

In partnership with ChartIQ

Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates

Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Mobilize your Website

View Site in Mobile | Classic

Share by: